These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15482168)

  • 61. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
    Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
    Castells L; Vargas V; Allende H; Bilbao I; Luis Lázaro J; Margarit C; Esteban R; Guardia J
    J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
    Meyer-Wyss B; Rich P; Egger H; Helbling B; Müllhaupt B; Rammert C; Gonvers JJ; Oneta C; Criblez D; Rossi L; Borovicka J; Meyenberger C; Arn M; Renner EL;
    J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Peginterferon-alfa-2b or -alfa-2a and ribavirin combined treatment in hepatitis C infection].
    Szalay F
    Orv Hetil; 2010 Feb; 151(7):271-3. PubMed ID: 20133247
    [No Abstract]   [Full Text] [Related]  

  • 65. Hepatitis C treatment, HAART and side effects.
    TreatmentUpdate; 2001; 13(7):7-8. PubMed ID: 11794865
    [No Abstract]   [Full Text] [Related]  

  • 66. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
    Glue P; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S; Clement RP
    Hepatology; 2000 Sep; 32(3):647-53. PubMed ID: 10960463
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
    Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
    Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
    Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Peginterferon-α-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation.
    Gordon FD; Kwo P; Ghalib R; Crippin J; Vargas HE; Brown KA; Schiano T; Chaudhri E; Pedicone LD; Brown RS
    J Clin Gastroenterol; 2012 Sep; 46(8):700-8. PubMed ID: 22739223
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.
    Kapol N; Lochid-Amnuay S; Teerawattananon Y
    BMC Gastroenterol; 2016 Aug; 16(1):91. PubMed ID: 27492396
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Peginterferon alfa-2b and ribavirin in thalassaemia/chronic hepatitis C virus-co-infected non-responder to standard interferon-based.
    Hamidah A; Thambidorai CR; Jamal R
    Med J Malaysia; 2005 Oct; 60(4):517-9. PubMed ID: 16570722
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antiviral therapy in chronic hepatitis E: a systematic review.
    Peters van Ton AM; Gevers TJ; Drenth JP
    J Viral Hepat; 2015 Dec; 22(12):965-73. PubMed ID: 25760481
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
    Hu CC; Chien RN
    Aliment Pharmacol Ther; 2013 Feb; 37(4):492. PubMed ID: 23336679
    [No Abstract]   [Full Text] [Related]  

  • 74. [Treatment of hepatitis C virus in HIV-positive patients].
    Mallolas Masferrer J; Martínez-Rebollar M; Laguno Centeno M
    Gastroenterol Hepatol; 2011 Oct; 34(8):558-67. PubMed ID: 21435743
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C.
    Wang LJ; Chen SW; Chen CK; Yen CL; Chang JJ; Lee TS; Liu CJ; Chen LW; Chien RN
    BMC Psychiatry; 2016 Nov; 16(1):424. PubMed ID: 27884134
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials.
    Fabrizi F; Dixit V; Martin P; Messa P
    J Viral Hepat; 2011 Jul; 18(7):e263-9. PubMed ID: 21108701
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.
    Jensen DM; Marcellin P; Freilich B; Andreone P; Di Bisceglie A; Brandão-Mello CE; Reddy KR; Craxi A; Martin AO; Teuber G; Messinger D; Thommes JA; Tietz A
    Ann Intern Med; 2009 Apr; 150(8):528-40. PubMed ID: 19380853
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Severe ocular bacterial infection associated with pegylated interferon and ribavirin treatment for hepatitis C].
    Khalil A; Gonzalez F; El Riachy E; Lucidarme D; Filoche B
    Gastroenterol Clin Biol; 2005 Nov; 29(11):1187-8. PubMed ID: 16505773
    [No Abstract]   [Full Text] [Related]  

  • 79. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia.
    Harmatz P; Jonas MM; Kwiatkowski JL; Wright EC; Fischer R; Vichinsky E; Giardina PJ; Neufeld EJ; Porter J; Olivieri N;
    Haematologica; 2008 Aug; 93(8):1247-51. PubMed ID: 18556414
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.
    Sulkowski MS; Cooper C; Hunyady B; Jia J; Ogurtsov P; Peck-Radosavljevic M; Shiffman ML; Yurdaydin C; Dalgard O
    Nat Rev Gastroenterol Hepatol; 2011 Apr; 8(4):212-23. PubMed ID: 21386812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.